Rule 1: Molecules that contain functional groups such as CN or NO2 have a high probability of causing adverse effects on the blood and lymphatic systems as they increase the reactivity of the molecule and lead to interactions with biological molecules.
Rule 2: Molecules that contain a benzene ring are likely to cause adverse effects on the blood and lymphatic systems due to its carcinogenic properties which can disrupt normal cell growth and division.
Rule 3: Molecules that contain a long carbon chain may have low toxicity but could potentially interfere with lipid metabolism in the body, leading to changes in cholesterol levels and other metabolic processes.
Rule 4: Compounds containing a sulfonamide group (-SO2NH-) may have adverse effects on the blood and lymphatic systems.
Rule 5: Compounds with a nitro group (-NO2) attached to an aromatic ring may also have adverse effects on the blood and lymphatic systems.
Rule 6: Compounds containing a halogen atom such as chlorine or fluorine may have adverse effects on the cardiovascular system.
Rule 7: Molecules containing a sulfonyl group (-SO2-) or a phosphate group (-OPO3-) may have potential to cause adverse effects in relation to blood and lymphatic system disorders.
Rule 8: Presence of functional groups such as carbonyl group (C=O) or carboxyl group (COOH) in a molecule increases its likelihood of causing adverse effects on the blood and lymphatic systems.
Rule 9: Molecules containing aromatic rings may have higher chances of causing adverse effects due to their ability to interact with biological receptors.
Rule 10: The molecular weight of a compound affects its bioavailability and toxicity. Smaller molecules tend to be more bioavailable and less toxic than larger ones.
Rule 11: Presence of functional groups such as "-COOH" or "-SO3H" in the molecular structure can lead to adverse effects on the blood and lymphatic systems.
Rule 12: Molecular structures containing a heterocyclic ring, especially those containing nitrogen atoms like pyridine or pyrimidine, may contribute to adverse effects on the blood and lymphatic systems.
Rule 13: Molecules with multiple aromatic rings connected by conjugated double bonds may increase ability to penetrate cell membranes and potentially cause adverse effects on the blood and lymphatic systems.
Rule 14: Molecules containing a cyano group (-CN) or a carbonyl group (-C=O) may have the potential to cause adverse effects in the blood and lymphatic systems. 
Rule 15: Molecules containing a sulfonate group (-SO3-) or a nitro group (-NO2) may have potential to cause adverse effects in the blood and lymphatic systems.
Rule 16: Molecules containing a carbonyl group (-C=O) connected to a double bond (=C=) followed by two carbon atoms may have potential to cause adverse effects in the blood and lymphatic systems.
Rule 17: Molecules containing a nitrogen atom bonded to four other atoms, including one oxygen atom, may have potential to cause adverse effects in the blood and lymphatic systems.
Rule 18: Compounds containing carboxylic acid groups (-COOH) may have adverse effects on the blood and lymphatic systems if they are conjugated with amines or amides.
Rule 19: Compounds with a nitro group (-NO2) may be associated with adverse effects on the blood and lymphatic systems due to its ability to form reactive intermediates under certain conditions.
Rule 20: If the molecular structure contains multiple aromatic rings and functional groups like "-COOH" or "-SO3H", then it may lead to adverse effects on the blood and lymphatic systems.
Rule 21: The size and shape of a molecule can determine its ability to cause adverse effects. Molecules that are too large or have a non-optimal shape may have difficulty penetrating cell membranes.
Rule 22: The charge and polarity of a molecule can affect its ability to cross cell membranes and reach target sites within the body. Neutral and charged molecules have different levels of bioavailability and toxicity.
Rule 23: The three-dimensional structure of a molecule plays a crucial role in determining its bioactivity and potency. A molecule with a linear structure may be less likely to cross cell membranes and interact with target proteins compared to a molecule with a bent or bulky structure.
Rule 24: The presence of certain functional groups in a molecule may increase its likelihood of causing adverse effects on the blood and lymphatic systems. For example, the presence of a carboxylic acid group (-COOH) or a sulfonamide group (-SO2NH2) in a molecule may increase its potential to disrupt the normal functioning of the immune system.
Rule 25: Compounds with aromatic rings attached tend to exhibit higher lipophilicity, making them more likely to cross cell membranes and increase potential toxic effects.
Rule 26: Molecules with high molecular weight and complexity often possess poor pharmacokinetic profiles that increase their risk of adverse reactions.
Rule 27: Certain atoms or bonds in a molecule can affect its toxicity. Halogen atoms such as chlorine or bromine, and nitrogen-containing heterocycles such as pyridine or pyrimidine rings, can increase a molecule's potential to cause adverse effects on the blood and lymphatic systems.
Rule 1: Molecules containing a sulfonyl group (-SO2-) or a carbonyl group (-C=O) in conjugation with an aromatic ring, may possibly have side effects on the blood and lymphatic systems due to increased binding to proteins involved in the regulation of blood clotting and immune responses.

Rule 2: Molecules with chlorine atoms could potentially cause adverse effects on the blood and lymphatic systems due to increased potential for toxicity.

Rule 3: Molecules containing arsenic atoms in their structure may exhibit a higher probability of causing adverse effects on the blood and lymphatic systems.

Rule 4: Presence of nitrogen atoms in a molecule's structure may lessen the likelihood of adverse effects on the blood and lymphatic systems. 

Rule 5: Molecules containing sulfonamide groups (-SO2NH2) or similar functional groups can potentially cause adverse effects on the blood and lymphatic systems due to increased allergic reactions and toxicity.

Rule 6: Molecules containing a halogen atom such as chlorine or fluorine, are at an increased risk for causing adverse effects on the blood and lymphatic systems due to heightened reactivity, leading to toxic reactions.

Rule 7: Molecules with a nitrogen-containing ring structure, such as pyridine or pyrimidine, can potentially cause adverse effects on the blood and lymphatic systems, as it is known to interact with biological molecules and disrupt cellular processes.

Rule 8: Molecules containing sulfonyl group (SO2R) may potentially have side effects on the blood and lymphatic systems due to increased reactivity with biological systems.

Rule 9: Molecules containing halogen atoms such as chlorine or fluorine at specific positions might have a higher risk of causing adverse effects on the blood and lymphatic systems due to heightened reactivity, leading to toxic reactions.

Rule 10: A molecule having a nitro group (NO2) attached to an aromatic ring may indicate a high likelihood of causing adverse effects on the blood and lymphatic systems due to increased reactivity with biological systems.

Rule 11: The presence of functional groups such as sulfonamide or nitro group in a compound implies a potential for side effects on the blood and lymphatic systems. 

Rule 12: A compound with aromatic rings that are substituted with functional groups like halogens or amines may also exhibit side effects.

Rule 13: Compounds having polar functional groups like carboxylic acid, hydroxyl, or amino groups may interact with biological molecules leading to toxicity.

Rule 14: If the molecule contains a benzene ring, it may have potential side effects on the blood and lymphatic systems due to potential for binding to proteins involved in these biological processes.

Rule 15: If the molecule contains a sulfonamide group, it may also exhibit toxicity towards the blood and lymphatic systems, as they are known to interfere with folic acid metabolism, which could cause health problems.

Rule 16: If the molecule contains a nitro group, it could potentially trigger allergic reactions and other immune responses, thus should be used with caution.

Rule 17: Molecules containing functional groups such as nitro group or fluorine increases its potential for causing adverse effects on the blood and lymphatic systems.

Rule 18: A compound containing a conjugated system of double bonds may have a higher probability of exhibiting toxicity towards the blood and lymphatic systems due to its potential for reactivity with biological systems. 

Rule 19: Compounds with a high degree of hydrophobicity tend to accumulate in lipid membranes and may disrupt their normal function, leading to adverse effects on the blood and lymphatic systems.

Rule 20: The presence of functional groups such as sulfonamide, carboxylic acid, or amide in a compound may increase its potential for causing adverse effects on the blood and lymphatic systems due to increased reactivity with biological systems. 

Rule 21: The presence of halogen atoms such as bromine or chlorine in the molecular structure may increase the likelihood of causing adverse effects on the blood and lymphatic systems due to increased potential for toxicity.

Rule 22: The presence of multiple double bonds between carbon atoms in the molecular structure indicates a higher likelihood of causing adverse effects on the blood and lymphatic systems due to potential increased reactivity and binding with proteins and enzymes in the body.

Rule 23: The presence of functional groups such as nitro group or fluorine in a compound may increase its potential for causing adverse effects on the blood and lymphatic systems due to increased reactivity with biological systems. 

Rule 24: If the molecule contains a carbonyl group (-C=O) connected to a nitrogen atom, it may also have the potential to cause adverse effects on the blood and lymphatic systems due to its potential for reactivity with biological systems.

Rule 25: If the molecule contains a sulfonamide group (-SO2NH2) or a halogen atom such as chlorine (Cl), it may have the potential to cause adverse effects on the blood and lymphatic systems due to increased allergic reactions and toxicity.

Rule 26: If the molecule contains a fluorine atom (F) at position 8 of the fluorene ring, it may not have the potential to cause adverse effects on the blood and lymphatic systems. 

Rule 27: If the molecule contains a zinc ion (Zn), then it may not have the potential to cause adverse effects on the blood and lymphatic systems.
Rule 1: A molecule may have the potential to cause adverse effects in the blood and lymphatic systems if it contains a chlorine atom attached to a carbon atom.
Rule 2: A molecule may have the potential to cause adverse effects in the blood and lymphatic systems if it contains a nitrogen atom bonded to four other atoms - specifically two carbon atoms, one oxygen atom, and one hydrogen atom.
Rule 3: A molecule may have the potential to cause adverse effects in the blood and lymphatic systems if it contains a benzene ring structure.
